SEC filing record
Primary Source · SEC.gov

Olema Pharmaceuticals, Inc.

2024 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalNew Form D filerForm D · 2024-12-122 events: 1 new form d filer, 1 large raiseLast filing 2024-12-12

Raised

$250M

Investors

26

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Olema Pharmaceuticals, Inc. is a Delaware corporation that first filed a Form D on August 27, 2018 and most recently amended it on December 12, 2024 in the Pharmaceuticals industry group. The offering claims Rule 506(b) and covers equity. Olema Pharmaceuticals, Inc. reported $249,999,225 sold from 26 investors of a $249,999,986 total offering as of the Form D filed December 12, 2024. The filing states that the figure is combined across related vehicles, so it is not this entity's figure alone. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names Jefferies LLC (CRD 2347), associated with None; J.P. Morgan Securities LLC (CRD 79), associated with None; Goldman Sachs & Co. LLC (CRD 361), associated with None; LifeSci Capital LLC (CRD 168404), associated with None and 3 others as recipients of sales compensation soliciting in all states. Sales commissions are reported as $12,500,000 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 365 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001750284
Entity NameOlema Pharmaceuticals, Inc.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address365 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080
Phone(415) 651-3316
Former NamesOlema Pharmaceuticals, Inc. (until November 10, 2026)
Industry / Fund TypePharmaceuticals
Securities TypeEquity
First Sale DateDecember 4, 2024
Filing DateDecember 12, 2024
Accession Number0001243233-24-000002
Total Offering Amount$249,999,986
Total Amount Sold$249,999,225
Amount Remaining$761
Amount Sold NoteCombined figure across related vehicles: The Total Offering Amount and Total Amount Remaining to be Sold include amounts that may be received by the Issuer upon exercise of pre-funded warrants at an exercise price of $0.0001 per pre-funded warrant.
Total Investors26
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Sales Commissions$12,500,000 (to Jefferies LLC and 6 others)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)CA
Amendment Count6 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

2

latest Dec 12, 2024

Critical / warning

0 / 0

2 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

5

closed, lapsed

Latest event New filer · Dec 12, 2024

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 2 filing events with values and deltas, latest 2024-12-12, and alerts on the next one
  • 5 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2024-12-12: 1 related person added and 0 removed against the filing of 2023-09-14; 13 now listed. The names are in the Terminal feed.

Sean Bohen, M.D., Ph.D.

Executive Officer, Director · San Francisco, CA

David C. Myles, Ph.D.

Executive Officer · San Francisco, CA

Shane C. Kovacs

Executive Officer · San Francisco, CA

Naseem C. Zojwalla, M.D.

Executive Officer · San Francisco, CA

Yi C. Larson

Director · San Francisco, CA

Andrew C. Rappaport

Director · San Francisco, CA

Cynthia C. Butitta

Director · San Francisco, CA

Cyrus L. Harmon, Ph.D.

Director · San Francisco, CA

Sandra L. Horning, M.D.

Director · San Francisco, CA

Gorjan L. Hrustanovic, Ph.D.

Director · San Francisco, CA

Graham L. Walmsley, M.D., Ph.D.

Director · San Francisco, CA

Ian L. Clark

Director · San Francisco, CA

Scott L. Garland

Director · San Francisco, CA

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Jefferies LLCCRD 2347 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in all states

J.P. Morgan Securities LLCCRD 79 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in all states

Goldman Sachs & Co. LLCCRD 361 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in all states

LifeSci Capital LLCCRD 168404 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in all states

Oppenheimer & Co. Inc.CRD 249 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in all states

H.C. Wainright & Co., LLChowCRD 375 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in all states

Citigroup Global Markets Inc.CRD 7059 on BrokerCheck

Associated broker-dealer: None · New York, NY · Soliciting in all states

Questions About Olema Pharmaceuticals, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Olema Pharmaceuticals, Inc.?

Olema Pharmaceuticals, Inc. is a Delaware corporation that filed a Form D with the SEC on December 12, 2024 in the Pharmaceuticals industry group. The filing claims Rule 506(b) for an offering of equity.

Is Olema Pharmaceuticals, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Olema Pharmaceuticals, Inc. filed a Form D with the SEC on December 12, 2024 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $249,999,225 sold to 26 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Olema Pharmaceuticals, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Olema Pharmaceuticals, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Olema Pharmaceuticals, Inc. raised?

Olema Pharmaceuticals, Inc. reported $249,999,225 sold from 26 investors of a $249,999,986 total offering as of the Form D filed December 12, 2024. The filing states that the figure is combined across related vehicles, so it is not this entity's figure alone.

Who can invest in Olema Pharmaceuticals, Inc.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Olema Pharmaceuticals, Inc.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Olema Pharmaceuticals, Inc. and how are they paid?

The Form D names Jefferies LLC (CRD 2347), associated with None; J.P. Morgan Securities LLC (CRD 79), associated with None; Goldman Sachs & Co. LLC (CRD 361), associated with None; LifeSci Capital LLC (CRD 168404), associated with None and 3 others as recipients of sales compensation soliciting in all states. Sales commissions are reported as $12,500,000 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Olema Pharmaceuticals, Inc.?

The Form D lists 13 related persons: Sean Bohen, M.D., Ph.D., executive officer, director; David C. Myles, Ph.D., executive officer; Shane C. Kovacs, executive officer; Naseem C. Zojwalla, M.D., executive officer; Yi C. Larson, director; Andrew C. Rappaport, director; Cynthia C. Butitta, director; Cyrus L. Harmon, Ph.D., director, and 5 more. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Olema Pharmaceuticals, Inc. located?

The issuer's address on its SEC filings is 365 Oyster Point Boulevard, Suite 400, South San Francisco, CA 94080. Its phone number of record is (415) 651-3316. It is organized under the laws of Delaware.

How long is the Olema Pharmaceuticals, Inc. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.

What is Olema Pharmaceuticals, Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.